|
A pivotal study led by Sandra Black has
demonstrated the efficacy of donepezil in patients living in
the community with severe AD, defined by MMSE scores of 1 to
12. This trial was key in the approval by Health Canada for
the use of donepezil at this stage of the disease. The new data
will have to be taken into account when studying the results
of the Third Canadian Consensus Conference on Dementia (CCCD),
to be released in the Canadian Medical Association Journal
using case vignettes and Alzheimer’s and Dementia
using review articles, such as the one by Herrmann, Gauthier
and Lysy.
Donepezil preserves cognition and
global function in patients with severe Alzheimer disease
(NEUROLOGY 2007;69:459-469)
S.E. Blac k, MD,
R. Doody, MD,
H. Li, PhD,
T. McRae, MD,
et al,
Toronto, ON,
Various centres, USA
Clinical practice guidelines for
severe Alzheimer’s disease
(Alzheimer’s & Dementia
2007;3[4]:A1-A16)
| this abstract is unavailable |
Nathan Herrman,
Serge Gauthier,
Paul G. Lysy
Toronto, ON,
Montreal, QC
|
